WO2002002148A3 - Dual recombinant gene therapy compositions and methods of use - Google Patents

Dual recombinant gene therapy compositions and methods of use Download PDF

Info

Publication number
WO2002002148A3
WO2002002148A3 PCT/US2001/021059 US0121059W WO0202148A3 WO 2002002148 A3 WO2002002148 A3 WO 2002002148A3 US 0121059 W US0121059 W US 0121059W WO 0202148 A3 WO0202148 A3 WO 0202148A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
gene therapy
compositions
therapy compositions
recombinant gene
Prior art date
Application number
PCT/US2001/021059
Other languages
French (fr)
Other versions
WO2002002148A2 (en
Inventor
Mei Hua Gao
Original Assignee
Collateral Therapeutics Inc
Mei Hua Gao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collateral Therapeutics Inc, Mei Hua Gao filed Critical Collateral Therapeutics Inc
Priority to AU2002216751A priority Critical patent/AU2002216751A1/en
Priority to EP01984094A priority patent/EP1294407A2/en
Priority to CA002412847A priority patent/CA2412847A1/en
Publication of WO2002002148A2 publication Critical patent/WO2002002148A2/en
Publication of WO2002002148A3 publication Critical patent/WO2002002148A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

The present invention relates to novel compositions and methods for the treatment of cardiovascular disease. More particularly, the invention relates to gene therapy compositions comprising at least two transgenes encoding angiogenic proteins or peptides. In one aspect the two transgenes are provided in a single gene delivery vector. Alternatively, the composition comprises at least two vectors, each vector comprising a transgene encoding a different angiogenic protein or peptide. The invention also relates to methods of treating cardiovascular disease using the gene therapy compositions; kits for gene delivery; and pharmaceutical compositions.
PCT/US2001/021059 2000-06-30 2001-06-28 Dual recombinant gene therapy compositions and methods of use WO2002002148A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002216751A AU2002216751A1 (en) 2000-06-30 2001-06-28 Dual recombinant gene therapy compositions and methods of use
EP01984094A EP1294407A2 (en) 2000-06-30 2001-06-28 Dual recombinant gene therapy compositions and methods of use
CA002412847A CA2412847A1 (en) 2000-06-30 2001-06-28 Dual recombinant gene therapy compositions and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60776600A 2000-06-30 2000-06-30
US09/607,766 2000-06-30
US82629101A 2001-04-03 2001-04-03
US09/826,291 2001-04-03

Publications (2)

Publication Number Publication Date
WO2002002148A2 WO2002002148A2 (en) 2002-01-10
WO2002002148A3 true WO2002002148A3 (en) 2002-10-17

Family

ID=27085582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021059 WO2002002148A2 (en) 2000-06-30 2001-06-28 Dual recombinant gene therapy compositions and methods of use

Country Status (4)

Country Link
EP (1) EP1294407A2 (en)
AU (1) AU2002216751A1 (en)
CA (1) CA2412847A1 (en)
WO (1) WO2002002148A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
US20020164310A1 (en) * 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
ES2222782B1 (en) * 2002-09-13 2006-03-01 Advanced In Vitro Cell Technoligies, S.L. METHOD FOR OBTAINING A SINGULAR CELL MODEL CAPABLE OF PLAYING IN VITRO THE METABOLIC IDIOSINCRASIA OF HUMAN BEINGS.
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
US9017661B2 (en) * 2011-02-22 2015-04-28 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
WO2019222455A1 (en) * 2018-05-16 2019-11-21 University Of Massachusetts Perfusion-based delivery of recombinant aav vectors for expression of secreted proteins
US11280884B2 (en) * 2018-08-30 2022-03-22 Photodigm Inc. LIDAR instrument and method for operating a LIDAR instrument
CA3142534A1 (en) * 2019-07-19 2021-01-28 University Of Florida Research Foundation, Incorporated Aav cardiac gene therapy for cardiomyopathy in humans
CA3165469A1 (en) * 2019-12-20 2021-06-24 Research Institute At Nationwide Children's Hospital Optimized gene therapy for targeting muscle in muscle diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998010071A1 (en) * 1996-09-06 1998-03-12 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2000040740A2 (en) * 1998-12-30 2000-07-13 Crucell Holland B.V. Gene therapy to promote angiogenesis
WO2001049325A2 (en) * 2000-01-07 2001-07-12 Stichting Klinische Farmacologie Groningen Gene therapy to promote angiogenesis and/or the treatment of heart failure

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011506A1 (en) * 1992-11-18 1994-05-26 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1998010071A1 (en) * 1996-09-06 1998-03-12 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
WO1998050079A2 (en) * 1997-05-06 1998-11-12 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999040945A2 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
WO2000040740A2 (en) * 1998-12-30 2000-07-13 Crucell Holland B.V. Gene therapy to promote angiogenesis
WO2001049325A2 (en) * 2000-01-07 2001-07-12 Stichting Klinische Farmacologie Groningen Gene therapy to promote angiogenesis and/or the treatment of heart failure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DULAK JOZEF ET AL: "Gene transfer of vascular endothelial growth factor and endothelial nitric oxide synthase - Implications for gene therapy in cardiovascular diseases", DIALOG BIOSIS PREVIEWS, XX, XX, vol. 51, no. 3, May 1999 (1999-05-01), pages 233 - 241, XP002138212 *
PEPPER M S ET AL: "Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 2, no. 189, 15 December 1992 (1992-12-15), pages 824 - 831, XP002078851, ISSN: 0006-291X *
YLA-HERTTUALA S S ET AL: "Cardiovascular gene therapy", LANCET, XX, XX, vol. 355, no. 9199, 15 January 2000 (2000-01-15), pages 213 - 222, XP004263017, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
EP1294407A2 (en) 2003-03-26
WO2002002148A2 (en) 2002-01-10
AU2002216751A1 (en) 2002-01-14
CA2412847A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
WO2004027019A3 (en) Improved raav expression systems for genetic modification of specific capsid proteins
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
MXPA02001878A (en) Novel b74 molecules and uses therefor.
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
WO2000046246A8 (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
GB9911683D0 (en) Antigenic peptides
WO2006131749A3 (en) Scaffold
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
HUP0100267A2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU5776799A (en) Modified hcv peptide vaccines
WO2002016591A3 (en) Human transporter family members and uses thereof
DE69712907D1 (en) IMMUNOGENIC TLP COMPOSITION
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
WO2001098355A3 (en) Cgi-69 compositions and methods of use
WO2001002429A3 (en) Angiopoietin-6 and uses thereof
WO2001092490A3 (en) Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof
WO2001081413A3 (en) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002018439A3 (en) 52991, a human transporter protein and uses therefor
EP1225182A3 (en) Human phospholipid transporter
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2003035840A3 (en) 69583 and 85924, novel human protein kinase family members and uses therefor
WO2003048188A3 (en) 15603, a human ion channel family member
WO2003002720A3 (en) 2150, a human protein kinase family member and uses therefor
WO2002024911A3 (en) 63760, a novel human transporter and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2412847

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002216751

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001984094

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984094

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001984094

Country of ref document: EP